To analyze imatinib-induced psoriasis systemically in order to make the clinician achieve a better comprehension.

One GIST patient with imatinib-induced psoriasis was reported. Combined with the literature, the clinical manifestation, treatment principles and its possible mechanism were summarized.

Psoriasis aggravated or induced by imatinib often appeared in 3 to 8 weeks after taking it. Patients always developed rash on his trunk and limbs or psoriasis nail. Treatment measures include using corticosteroid and ultraviolet therapy or taking methotrexate, and drug withdrawal is required when necessary. After the rash controlled expectedly, it was expected to continue to take imatinib. The second-generation TKIs may be considered as an alternative treatment in patients whose rash break out repeatedly and difficult to control. Its pathogenesis may be related to the inhibition of T cells and cytokines.

The psoriasis should be seriously cared during the treatment with imatinib, the treatments for the symptoms and the close observation should be applied in time. It is expected to continue to take imatinib until the symptoms are well controlled. If needed, replace the imatinib with second-generation TKIs.